Show simple item record

dc.contributor.author Cahill, Mary R.
dc.contributor.author Colvin, B. T.
dc.date.accessioned 2011-11-16T10:47:48Z
dc.date.available 2011-11-16T10:47:48Z
dc.date.issued 1997-04
dc.identifier.citation Cahill Mary R.; Colvin BT (1997) 'Haemophilia'. Postgraduate Medical Journal, 73 (858):201-206. en
dc.identifier.volume 73 en
dc.identifier.issued 858 en
dc.identifier.startpage 201 en
dc.identifier.endpage 206 en
dc.identifier.uri http://hdl.handle.net/10468/452
dc.identifier.doi 10.1136/pgmj.73.858.201
dc.description.abstract Although the nature of haemophilia has been understood for thousands of years, knowledge of its molecular genetics is recent. These X-linked bleeding disorders have diverse underlying DNA defects and, in 1992, DNA inversion within the X chromosome was found to explain half of the most serious cases of haemophilia A. The life-span and quality of-life for patients with haemophilia had improved steadily throughout the early 1980s but the principal cause of death remained intracranial haemorrhage until the epidemic of HIV infection due to contaminated factor concentrates. Infection with hepatitis C virus is almost universal for patients treated with clotting factors before 1985. No curative treatment is available for hepatitis C at present. Knowledge of the transmission of viruses in concentrates has led to important developments in processing techniques to eliminate them. Recombinant technology has produced factor VIII and, more recently, factor IX concentrate which is likely to be very safe. Development of inhibitors to factor concentrates (especially factor VIII) remains one of the most serious complications of haemophilia. The variety of treatments available testifies to the lack of a single universally efficacious one. The use of prophylactic treatment has been conclusively demonstrated to result in a preservation of joint function in severely affected patients who might otherwise develop significant joint problems. The many facets of the care of patients with severe haemophilia, ranging from dental care to genetic counselling, can be advantageously co-ordinated in a haemophilia comprehensive care centre. en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.relation.uri http://pmj.bmj.com/content/73/858/201
dc.rights ©The Fellowship of Postgraduate Medicine, 1997 en
dc.subject Haemophilia en
dc.subject Recombinant factor replacement en
dc.subject Prophylaxis en
dc.subject Genetics en
dc.subject.lcsh Hemophilia en
dc.title Haemophilia en
dc.type Article (peer-reviewed) en
dc.internal.authorurl http://publish.ucc.ie/researchprofiles/C006/maryrcahill en
dc.internal.authorcontactother Mary Cahill, Pathology, University College Cork, Cork, Ireland. +353-21-490-3000 Email: maryr.cahill@hse.ie en
dc.internal.availability Full text available en
dc.date.updated 2011-11-10T12:45:33Z
dc.description.version Published Version en
dc.internal.rssid 348917
dc.description.status Peer reviewed en
dc.identifier.journaltitle Postgraduate Medical Journal en
dc.internal.copyrightchecked Yes Sherpa RoMEO en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress martina.hayes@ucc.ie en

Files in this item

This item appears in the following Collection(s)

Show simple item record

This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement